Trial Profile
Intensification of HAART with Maraviroc (MVC) as first line therapy of HIV-1-infected patients to rapidly suppress viral replication and minimize the evolution of drug-resistant variants.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2011
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- 05 Jul 2011 New trial record